Teprotumumab API is a fully human recombinant IgG1 monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R). Teprotumumab is produced using Chinese hamster ovary (CHO-DG44) cells and has an approximate molecular weight of 148 kDa. The FDA identifies teprotumumab-trbw as an IGF-1R inhibitor and describes it as a fully human IgG1 monoclonal antibody.
Teprotumumab is the active substance in TEPEZZA and is supplied as a sterile, preservative-free, white to off-white lyophilized powder for intravenous infusion. The FDA-approved presentation contains 500 mg per single-dose vial.
Teprotumumab is also known by the development names RG-1507, R-1507, RO-4858696 and HZN001. PubChem and the FDA Global Substance Registration System identify CAS 1036734-93-6 and UNII Y64GQ0KC0A for teprotumumab.
As a monoclonal antibody API, teprotumumab requires biologics-specific quality characterization rather than the conventional small-molecule API testing approach. Important quality attributes include identity, purity, aggregation, charge variants, potency, protein concentration, glycosylation and process-related impurities.
Teprotumumab is a recombinant human IgG1κ monoclonal antibody directed against IGF-1R. It binds IGF-1R and inhibits receptor activation and downstream signaling. FDA regulatory review describes the antibody as approximately 148 kDa in intact molecular weight.
Because teprotumumab is a large protein biologic, its molecular characteristics are evaluated through orthogonal analytical methods such as chromatographic, electrophoretic, spectroscopic and biological assays rather than relying only on molecular-weight and purity measurements used for conventional APIs.
Teprotumumab binds to insulin-like growth factor-1 receptor (IGF-1R) and blocks its activation and signaling. The FDA describes IGF-1R inhibition as the principal pharmacological action of teprotumumab-trbw.
The IGF-1R pathway is involved in signaling associated with orbital fibroblasts and tissue remodeling. By inhibiting this pathway, teprotumumab can reduce pathological processes associated with thyroid eye disease. The EMA describes teprotumumab as targeting the IGF-1R/TSH-receptor signaling complex involved in thyroid eye disease.
Teprotumumab is used in the treatment of Thyroid Eye Disease (TED), also known as Graves' eye disease. The current FDA labeling indicates TEPEZZA for treatment of thyroid eye disease regardless of disease activity or duration.
The European Medicines Agency lists Tepezza for the treatment of moderate to severe thyroid eye disease in adults.
Quality control for Teprotumumab API should be based on biologic-specific analytical characterization. Typical quality attributes include:
The FDA's CMC review describes teprotumumab drug substance and drug product potency testing against a qualified working/reference standard and identifies its recombinant CHO-cell manufacturing platform.
Teprotumumab is manufactured as a recombinant monoclonal antibody using CHO-DG44 cells. Manufacturing of this type of biologic requires controlled upstream cell culture, downstream purification, viral safety controls, formulation and aseptic processing.
A qualified Teprotumumab API Manufacturer in India should therefore maintain appropriate biologics manufacturing controls, validated analytical methods, traceability and documentation supporting batch-to-batch consistency.
| Property | Value |
|---|---|
| API Name | Teprotumumab |
| Proper name | Teprotumumab-trbw |
| CAS No. | 1036734-93-6 |
| FDA UNII | Y64GQ0KC0A |
| Antibody class | Fully human IgG1 monoclonal antibody |
| Target | IGF-1 receptor (IGF-1R) |
| Production system | CHO-DG44 cells |
| Approx. molecular weight | 148 kDa |
| Finished-product strength | 500 mg/vial |
| Finished-product appearance | White to off-white lyophilized powder |
| Reconstituted concentration | 47.6 mg/mL |
| Reconstituted pH | 5.5 |
The 500 mg/vial strength, 47.6 mg/mL reconstituted concentration and pH 5.5 are FDA product values; they should not be interpreted as universal drug-substance API specifications.
The approved finished product is supplied in a single-dose vial as a sterile, preservative-free lyophilized powder. FDA information specifies storage of the drug product at 2°C to 8°C, protected from light.
For bulk API or drug-substance supply, packaging and storage should follow the validated manufacturer-specific stability program and approved product specifications.
A professional Teprotumumab API supply program may include:
A reliable Teprotumumab API Manufacturer in India should provide biologics-focused quality control, validated analytical characterization, controlled manufacturing processes and comprehensive documentation. Since teprotumumab is a monoclonal antibody rather than a conventional small-molecule API, supplier qualification should place particular emphasis on protein identity, purity, aggregation, potency, process-related impurities and consistency between batches.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| pH (1% Solution) | 5.5 |
| Solubility | 47.6 mg/mL after reconstitution with 10 mL Sterile Water for Injection; pH 5.5 |